Magnesium Shows Moderate Antidepressant and Mild Anxiolytic Effects in Systematic Review

Magnesium supplementation may modestly reduce symptoms of depression and anxiety, particularly in people with low magnesium levels, chronic stress, or incomplete response to standard antidepressants, according to a systematic review published in Food Production, Processing and Nutrition. The review, conducted under PRISMA 2020 guidelines, synthesized 21 human studies drawn from more than 1,300 records identified in PubMed, Scopus, Embase and PsycINFO, covering literature published between January 2000 and June 2026. The evidence base comprised nine randomized controlled trials, eight observational studies and four existing systematic reviews or meta-analyses, together encompassing more than 5,000 participants.

Because the included studies differed so widely in design, populations, formulations and outcome measures, the authors did not perform a new meta-analysis. Instead, they carried out a structured narrative synthesis, extracting quantitative estimates such as standardized mean differences and 95 percent confidence intervals from existing trials and meta-analyses without any new statistical pooling. The most recent meta-analysis they cited, by Moabedi and colleagues in 2023, reported a pooled standardized mean difference of minus 0.92 for depressive symptoms, with a 95 percent confidence interval of minus 1.443 to minus 0.396 and substantial heterogeneity, with an I-squared value of 75.6 percent. Subgroup analyses in that meta-analysis suggested the effect size varied by the depression assessment instrument used and by study location, and that doses of 250 mg per day or less may be associated with larger reductions in depression scores than higher doses.

Across the randomized trials and meta-analyses reviewed, magnesium supplementation produced small-to-moderate improvements in depressive and anxiety scores, with standardized mean differences of roughly minus 0.4 to minus 0.9 and statistical significance below the 0.05 threshold. Individual trials showed consistent reductions in PHQ-9 and BDI-II scores within six weeks. Interventions typically involved oral magnesium citrate, oxide or glycinate at doses of 200 to 500 mg per day administered over four to twelve weeks. Combination regimens pairing magnesium with vitamin B6 or vitamin D yielded greater effects on stress and quality-of-life indices, and in randomized trials magnesium alone or with vitamin B6 significantly improved DASS-42 scores within four to eight weeks, with the combination producing faster and stronger benefits.

Not every interventional study was positive. In a triple-blind randomized trial of 99 postpartum women without pre-existing depression, Fard and colleagues found that 320 mg per day of magnesium sulfate, equivalent to 64.6 mg of elemental magnesium, taken for eight weeks did not significantly reduce Edinburgh Postnatal Depression Scale scores or Spielberger State-Trait Anxiety Inventory scores compared with placebo after adjustment for baseline scores and serum mineral levels. The review’s authors highlight this adequately powered null study as important, arguing that the scarcity of such negative findings in the literature, alongside a predominance of small positive trials, may inflate pooled effect estimates and distort the true therapeutic signal.

Biological marker outcomes were also mixed. In one randomized trial, magnesium combined with vitamin D significantly lowered serum interleukin-6 concentrations relative to placebo in obese women with depressive symptoms, pointing to a possible anti-inflammatory pathway. Conversely, another trial observed no significant change in serum brain-derived neurotrophic factor following magnesium oxide supplementation despite clinical improvement, suggesting that magnesium may exert anti-inflammatory effects independently of short-term changes in peripheral neuroplasticity markers. The reviewers note that such divergence indicates peripheral biomarkers do not fully capture the mechanism of clinical improvement.

Observational evidence consistently linked lower magnesium intake or serum levels with a higher depressive symptom burden. A nationally representative United States sample showed that elevated magnesium depletion scores correlated with increased depressive symptom severity. The large Hordaland Health Study in Norway demonstrated an inverse association between dietary magnesium intake and depression and anxiety scores in community-dwelling adults, and a 20-year prospective Finnish cohort linked lower dietary magnesium intake to higher depression incidence. Cross-sectional evidence from Iranian postgraduate students additionally showed that magnesium intake below dietary reference levels was associated with higher depression scores. Because serum magnesium represents only a small fraction of total body stores, the authors caution that subclinical deficiency may be underrecognized in clinical practice.

Applying the GRADE framework, the reviewers rated the certainty of evidence for depressive-symptom reduction as moderate, downgraded for heterogeneity and sample size, and the certainty for anxiety reduction as low to moderate. Methodological appraisal indicated overall moderate-to-high quality across the human studies. For depressive outcomes, six of nine randomized trials were rated low risk of bias, supporting a low-risk overall judgment for that outcome, while most anxiety trials carried moderate concerns regarding sample size and reliance on self-report measures. Downgrading criteria included limitations in randomization and blinding, imprecision with fewer than 400 participants, inconsistency above 40 percent I-squared, and indirectness from combined nutrient arms. No studies were excluded solely on the basis of bias rating; instead, certainty was downgraded within GRADE to reflect these limitations.

The mechanistic case for magnesium rests largely on preclinical work, which the authors deliberately separated from their clinical synthesis. Magnesium acts as a physiological, voltage-dependent antagonist of N-methyl-D-aspartate receptors, limiting calcium influx and preventing glutamatergic hyperactivation, and it enhances GABA-mediated inhibition. It also participates in monoamine synthesis and neuroplastic processes through upregulation of brain-derived neurotrophic factor, and deficiency has been linked in animal models to hypothalamic-pituitary-adrenal axis hyperactivation and heightened anxiety. The review is explicit that these mechanisms, drawn from in vitro and animal studies summarized in a supplementary appendix, have not been prospectively validated as mediators of clinical outcomes in human trials, and that mechanistic plausibility does not confirm clinical efficacy.

On the clinical interpretation, the authors propose that magnesium is best understood not as a conventional antidepressant but as a homeostatic modulator of stress-reactive neural circuits, with effects concentrated in a specific phenotype characterized by chronic stress exposure, comorbid anxiety, autonomic hyperarousal and documented hypomagnesemia. As a monotherapy, magnesium showed efficacy in mild-to-moderate depression, with one trial reporting rapid symptom reduction within two weeks of magnesium chloride supplementation and another demonstrating significant improvement in depressed patients with documented hypomagnesemia. As an adjunct to selective serotonin reuptake inhibitors, adding 250 mg per day of magnesium produced greater Beck Depression Inventory score reductions than SSRI monotherapy alone in one trial. The reviewers conclude that current evidence does not support magnesium as a standalone therapy for major depressive disorder, though it appears a well-tolerated, low-cost adjunctive option.

Several limitations temper the findings. No included trial exceeded twelve weeks of follow-up, and none assessed long-term maintenance effects, relapse rates or safety beyond six months, leaving the durability of any benefit unknown. Small samples, heterogeneous dosing and formulations, short intervention durations, variable diagnostic criteria and reliance on self-reported scales all limited precision and comparability, and publication bias cannot be ruled out despite no major funnel plot asymmetry in prior meta-analyses. None of the included trials performed item-level or symptom-network analyses, so it remains unclear whether magnesium preferentially improves specific symptoms such as sleep disturbance, somatic anxiety, fatigue or irritability rather than total scale scores. The authors call for large, multicenter, biomarker-guided randomized trials with standardized formulations, extended follow-up and mechanistic endpoints including BDNF, cortisol and interleukin-6 to confirm efficacy, define optimal dosing and establish magnesium’s role within precision psychiatry.

Subject of Research: Magnesium supplementation for depression and anxiety symptoms

Article Title: Magnesium supplementation for anxiety and depression: a systematic review of clinical evidence and mechanistic insights

Article References: Campedelli, L., Cicoli, A., Lastretti, M., Spagna, S., & D’Aleo, E. (2026). Magnesium supplementation for anxiety and depression: a systematic review of clinical evidence and mechanistic insights. Food Production, Processing and Nutrition, 8(1), Article 73. https://doi.org/10.1186/s43014-026-00424-6

Image Credits: AI Generated

DOI: 10.1186/s43014-026-00424-6

Keywords: magnesium, depression, anxiety, systematic review, nutritional psychiatry, NMDA receptor, GABA, GRADE certainty, randomized controlled trials, supplementation, HPA axis, precision psychiatry